Palatin Technologies, Inc.
AMEX: PTN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange American
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Carl Spana
- Employees
- 30
- Headquarters
- Cranbury, United States
- IPO year
- 1997
- Market cap
- $304.8M
- Website
- https://palatin.com
Loading PTN…
Loading profile data…Frequently asked questions about PTN
What does Palatin Technologies, Inc. (PTN) do?
Palatin Technologies, Inc. is a biopharmaceutical firm specializing in the creation of precise, receptor-targeting treatments for various medical conditions throughout the United States. Its flagship product is Vyleesi, a melanocortin receptor (MCr) agonist prescribed for premenopausal women experiencing hypoactive sexual desire disorder. The co...
Where does PTN trade?
Palatin Technologies, Inc. (PTN) trades on the New York Stock Exchange American.
What sector is PTN in?
Palatin Technologies, Inc. (PTN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Palatin Technologies, Inc.?
Carl Spana is the chief executive officer of Palatin Technologies, Inc. (PTN).
Where is Palatin Technologies, Inc. headquartered?
Palatin Technologies, Inc. is headquartered in United States.
Does PTN pay a dividend?
Palatin Technologies, Inc. (PTN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PTN go public?
Palatin Technologies, Inc. (PTN) completed its initial public offering in 1997.